TABLE 3.
Associations of oral glucocorticoid use and patient reported outcomes with achieving aggregate improvement score (AIS) minimal clinically important difference (MCID) (≤−10)
| AIS ≤−10 | AIS >−10 |
Change across AIS MCID
Crude OR (95% CI) |
Change across AIS MCID
Age- and sex-adjusted OR (95% CI) |
|
| Patients | 62 | 39 | ||
| Glucocorticoid use across AIS MCID | ||||
| Median daily prednisolone (mg) V1 | 11.2 (8.4–15.0) | 12.3 (8.7–14.6) | 0.99 (0.94–1.04) | 0.99 (0.94–1.04) |
| Median daily prednisolone (mg) V2 | 6.5 (2.2–8.5) | 7.8 (4.0–9.4) | 0.96 (0.91–1.03) | 0.96 (0.91–1.03) |
| Receiving maintenance prednisolone V1 | 49 (79.0) | 34 (87.2) | 0.55 (0.18–1.70) | 0.58 (0.18–1.80) |
| Receiving maintenance prednisolone V2 | 27 (43.5) | 25 (64.1) | 0.45 (0.20–1.02) | 0.40 (0.17–0.96) |
| Number of glucocorticoid rescue courses V1 | 5 (2–7) | 5 (3–8) | 0.96 (0.85–1.08) | 0.96 (0.85–1.08) |
| Number of glucocorticoid rescue courses V2 | 1 (0–2) | 2 (0–3) | 0.73 (0.55–0.98) | 0.70 (0.52–0.94) |
| Decrease annual prednisolone (mg) | −1925 (−1400–−2888) | −1727.5 (−2527–−1200) | 0.98 (0.94–1.02) | 0.98 (0.94–1.01) |
| Percentage decrease annual prednisolone | 48.6 (34.8–70.0) | 40.8 (26.1–57.2) | 0.80 (0.66–0.96) | 0.80 (0.66–0.97) |
| Baseline glucocorticoid-associated toxicity score | 165.5 (124–211) | 164 (129–229) | 1.00 (0.99–1.01) | 1.00 (0.99–1.01) |
| Change in PROMs across AIS MCID | ||||
| Mini-AQLQ | 0.82 (−0.7–1.6) | 0.94 (0.03–−1.7) | 0.91(0.67–1.23) | 0.93 (0.68–1.28) |
| SGRQ | −13.3 (−23.4–−4.6) | −9.9 (−15.8–4.6) | 0.99 (0.97–1.01) | 0.99 (0.96–1.01) |
| ACQ5 | −0.6 (−1.4–0.0) | −0.8 (−2.2–0.0) | 1.26 (0.91–1.75) | 1.29 (0.92–1.81) |
| HADS anxiety | −1.0 (−3.0–0.8) | −1.0 (−2.0–1.5) | 0.94 (0.83–1.07) | 0.95 (0.83–1.08) |
| HADS depression | −1.0 (−3.0–1.0) | −1 (−2.0–0.3) | 0.95 (0.85–1.07) | 0.94 (0.84–1.06) |
| EuroQoL-5L5D index | 0.0 (−0.08–0.1) | 0.02 (−0.06–0.1) | 1.29 (0.24–6.86) | 1.43 (0.26–7.99) |
| EuroQoL-5L5D health scale | 5 (−1–16.3) | 12 (−4–24) | 1.00 (0.97–1.02) | 1.00 (0.97–1.02) |
Data are presented as n, median (interquartile range) or n (%), unless otherwise stated. V1: at commencement of mepolizumab; V2: after 12 months treatment; PROMs: patient-reported outcome measures; AQLQ: Asthma Quality of Life Questionnaire; SGRQ: St George's Respiratory Questionnaire; ACQ: Asthma Control Questionnaire; HADS: Hospital Anxiety and Depression Scale.